Table 1 Characteristics of studies included in the meta-analysis
From: Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis
Study | Year | Country | Cancer types | Sample size | Cut-off | Age | Follow-up (month) | Survival analysis | HR | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|
Zhou | 2017 | China | DLBCL | 161 | 14.1 | 59 (18–80) | 42 (6–120) | OS, PFS | Reported | 7 |
Wang | 2017 | China | MM | 196 | 18.05 | 65 (33–82) | 33.5 (1–120) | OS | Reported | 7 |
Meng | 2017 | China | MM | 166 | 14 | 61.6 | 17.79 (0.63–62.83) | OS, PFS | Reported | 4 |
Luo | 2017 | China | NK/T lymphoma | 191 | 46.2a | 44 (15–86) | 30 (2–97) | OS, PFS | Reported | 7 |
Perisa | 2015 | Croatia | DLBCL | 81 | 15 | 64 | NR | OS, EFS | Reported | 5 |
Iriyama | 2015 | Japan | CML | 90 | 15 | NR | 168 | OS, EFS | Estimated | 5 |
Lee | 2014 | Korea | MM | 146 | 14.5 | 61 (32–83) | 120 | PFS | Reported | 6 |